Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donna Mildvan

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
The Journal of Infectious Diseases|January 15, 2004
Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trialJoseph J Eron, Judith Feinberg, Harold A Kessler, et al.
The Journal of Infectious Diseases|March 19, 2010
The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infectionMartin Markowitz, Florin Vaida, C Bradley Hare, et al.
The Journal of Infectious Diseases|November 17, 2006
A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024)J Michael Kilby, R Pat Bucy, Donna Mildvan, et al.
AIDS Research and Human Retroviruses|June 25, 2002
Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2Beverly E Sha, Hernan Valdez, Rebecca S Gelman, et al.
Vaccine|May 20, 2009
A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapyRajesh T Gandhi, David O'Neill, Ronald J Bosch, et al.
Nature Medicine|July 15, 2009
Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1Angela Meier, J Judy Chang, Ellen S Chan, et al.
The Journal of Infectious Diseases|August 10, 2006
Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068Jeffrey M Jacobson, R Pat Bucy, John Spritzler, et al.
Chest|June 21, 2020
Treatment of Community-Acquired Pneumonia in Immunocompromised Adults: A Consensus Statement Regarding Initial StrategiesJulio A Ramirez, Daniel M Musher, Scott E Evans, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
The Journal of Infectious Diseases|January 15, 2004
Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trialJoseph J Eron, Judith Feinberg, Harold A Kessler, et al.
The Journal of Infectious Diseases|March 19, 2010
The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infectionMartin Markowitz, Florin Vaida, C Bradley Hare, et al.
The Journal of Infectious Diseases|November 17, 2006
A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024)J Michael Kilby, R Pat Bucy, Donna Mildvan, et al.
AIDS Research and Human Retroviruses|June 25, 2002
Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2Beverly E Sha, Hernan Valdez, Rebecca S Gelman, et al.
Vaccine|May 20, 2009
A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapyRajesh T Gandhi, David O'Neill, Ronald J Bosch, et al.
Nature Medicine|July 15, 2009
Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1Angela Meier, J Judy Chang, Ellen S Chan, et al.
The Journal of Infectious Diseases|August 10, 2006
Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068Jeffrey M Jacobson, R Pat Bucy, John Spritzler, et al.
Chest|June 21, 2020
Treatment of Community-Acquired Pneumonia in Immunocompromised Adults: A Consensus Statement Regarding Initial StrategiesJulio A Ramirez, Daniel M Musher, Scott E Evans, et al.
Pageof 5